JEMPERLI 多塔利单抗 dostarlimab

Drug Class

PD-1 blocking antibody

Mechanism

Dostarlimab binds to the PD-1 receptor on T-cells, blocking its interaction with ligands PD-L1 and PD-L2, thereby restoring T-cell anti-tumor activity.

Approved Indication

Treatment of adult patients with mismatch repair deficient (dMMR) recurrent or advanced endometrial cancer, or other dMMR recurrent or advanced solid tumors.

What This Means For Patients

JEMPERLI 多塔利单抗 is not distributed through mainland China's retail pharmacy network. Uwell Cloud can help arrange a purchase channel for this medicine, sourced and dispatched from Hong Kong; clinical administration support in China can be coordinated on request. Availability and eligibility for any specific patient are determined by clinical review.

Regulatory Approvals

• FDA — Approved (2021) — Sources
• EMA — Approved (2021) — Sources

Pivotal Clinical Evidence

• GARNET — Oaknin et al., Clin Cancer Res 2022 (NCT02715284) — Sources

Sources

• https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761174s000lbl.pdf
• https://www.ema.europa.eu/en/medicines/human/EPAR/jemperli
• https://doi.org/10.1158/1078-0432.CCR-22-3915